Aliases & Classifications for Motion Sickness

MalaCards integrated aliases for Motion Sickness:

Name: Motion Sickness 57 12 25 43 44 15 73
Airsickness 25 73
Carsickness 25 73
Seasickness 25 73
Travel Sickness 12
Riders' Vertigo 25

Characteristics:

OMIM:

57
Inheritance:
not likely mendelian, but shows familial aggregation


Classifications:



External Ids:

OMIM 57 158280
Disease Ontology 12 DOID:2951
ICD10 33 T75.3
ICD9CM 35 994.6
MeSH 44 D009041
NCIt 50 C34824
SNOMED-CT 68 37031009
MedGen 42 C0026603
SNOMED-CT via HPO 69 88425004

Summaries for Motion Sickness

MedlinePlus : 43 Motion sickness is a common problem in people traveling by car, train, airplanes, and especially boats. Anyone can get it, but it is more common in children, pregnant women, and people taking certain medicines. Motion sickness can start suddenly, with a queasy feeling and cold sweats. It can then lead to dizziness and nausea and vomiting. Your brain senses movement by getting signals from your inner ears, eyes, muscles, and joints. When it gets signals that do not match, you can get motion sickness. For example, if you are reading on your phone while riding a bus, your eyes are focused on something that is not moving, but your inner ear senses motion. Where you sit can make a difference. The front seat of a car, forward cars of a train, upper deck on a boat or wing seats in a plane may give you a smoother ride. Looking out into the distance - instead of trying to read or look at something in the vehicle - can also help. Centers for Disease Control and Prevention

MalaCards based summary : Motion Sickness, also known as airsickness, is related to space motion sickness and meniere disease, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Motion Sickness is HTR3A (5-Hydroxytryptamine Receptor 3A), and among its related pathways/superpathways are Monoamine GPCRs and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Histamine and Promethazine have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and skin, and related phenotypes are abnormality of the nervous system and behavior/neurological

Genetics Home Reference : 25 Motion sickness is a common condition characterized by a feeling of unwellness brought on by certain kinds of movement. The usual symptoms include dizziness, pale skin (pallor), and sweating, followed by nausea and vomiting. Affected individuals may also experience rapid breathing (hyperventilation), headache, restlessness, and drowsiness. These symptoms can be triggered by many kinds of motion, particularly traveling in a car, bus, train, airplane, or boat. Amusement park rides, skiing, and virtual reality environments can also induce motion sickness.

Wikipedia : 76 Motion sickness is a condition in which a disagreement exists between visually perceived movement and... more...

Description from OMIM: 158280

Related Diseases for Motion Sickness

Diseases related to Motion Sickness via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Related Disease Score Top Affiliating Genes
1 space motion sickness 33.6 FOS AVP
2 meniere disease 30.2 FAM136A AQP1
3 migraine with or without aura 1 29.1 TAC1 HTR7 HTR3A HTR1A FOS
4 social phobia 10.2 HTR3A HTR1A
5 premature ejaculation 10.2 HTR3A HTR1A
6 psychosexual disorder 10.2 HTR7 HTR1A
7 kleptomania 10.1 HTR7 HTR1A
8 functional gastric disease 10.1 HTR7 HTR3A
9 dyspepsia 10.1 HTR3A HTR1A
10 intermittent explosive disorder 10.1 HTR7 HTR1A
11 pica disease 10.1
12 rumination disorder 10.1 HTR7 HTR3A HTR1A
13 central pontine myelinolysis 10.1 AVP AQP1
14 mental depression 10.1 HTR7 HTR1A
15 brunner syndrome 10.1 HTR7 HTR3A HTR1A
16 superior mesenteric artery syndrome 10.1 HTR3A AVP
17 amnestic disorder 10.1 HTR7 HTR3A HTR1A
18 impaired renal function disease 10.1 AVP AQP1
19 serotonin syndrome 10.0 TAC1 HTR3A HTR1A
20 anxiety 10.0
21 scoliosis 10.0
22 idiopathic scoliosis 10.0
23 syncope 10.0
24 endogenous depression 10.0 HTR7 HTR1A
25 functional diarrhea 10.0 TAC1 HTR7 HTR3A
26 irritable bowel syndrome 10.0 TAC1 HTR7 HTR3A
27 peripheral vertigo 10.0 FAM136A AVP
28 diabetes insipidus, nephrogenic, autosomal 10.0 AVP AQP1
29 carotid artery dissection 10.0 ZNF451 AVP
30 generalized anxiety disorder 10.0 HTR3A HTR1A
31 vestibular disease 10.0 FAM136A AVP
32 withdrawal disorder 9.9 HTR7 FOS
33 drug psychosis 9.9 HTR7 HTR1A FOS
34 drug-induced mental disorder 9.9 HTR7 HTR1A FOS
35 disease of mental health 9.9 HTR7 HTR1A FOS
36 carney complex, type 1 9.8
37 helicobacter pylori infection 9.8
38 caronte 9.8
39 orthostatic intolerance 9.8
40 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.8
41 osteoarthritis 9.8
42 spinal cord injury 9.8
43 thrombosis 9.8
44 plague 9.8
45 hyperglycemia 9.8
46 retinal degeneration 9.8
47 pathologic nystagmus 9.8
48 mal de debarquement syndrome 9.8
49 hypoxia 9.8
50 headache 9.8

Graphical network of the top 20 diseases related to Motion Sickness:



Diseases related to Motion Sickness

Symptoms & Phenotypes for Motion Sickness

Symptoms via clinical synopsis from OMIM:

57
Neuro:
motion sickness


Clinical features from OMIM:

158280

Human phenotypes related to Motion Sickness:

32
# Description HPO Frequency HPO Source Accession
1 abnormality of the nervous system 32 HP:0000707

UMLS symptoms related to Motion Sickness:


nausea and vomiting, constipation, fever, polydipsia, fatigue, abdominal pain, edema, pruritus, vertigo, pain, chest pain, diarrhea, headache, syncope, cyanosis, nausea, chronic pain, sciatica, asthenia, chills, renal colic, pelvic pain, coughing, icterus, signs and symptoms, signs and symptoms, digestive, hot flushes, vertigo/dizziness, dyspepsia, heartburn, gastrointestinal gas, symptoms, eye manifestations, halitosis, oral manifestations, vomiting alone, urological manifestations, hypertriglyceridemic waist, body temperature changes, signs and symptoms, respiratory, skin manifestations, mobility limitation, prodromal symptoms, medically unexplained symptoms

MGI Mouse Phenotypes related to Motion Sickness:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.81 ADRA2A AQP1 AVP FOS HTR1A HTR3A
2 mortality/aging MP:0010768 9.56 ADRA2A AQP1 AVP EXT2 FOS HTR1A
3 nervous system MP:0003631 9.17 ADRA2A AQP1 AVP FOS HTR1A HTR3A

Drugs & Therapeutics for Motion Sickness

Drugs for Motion Sickness (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 92)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 51-45-6, 75614-87-8 774
2
Promethazine Approved, Investigational Phase 4,Not Applicable 60-87-7 4927
3
Diphenhydramine Approved, Investigational Phase 4,Not Applicable 147-24-0, 58-73-1 3100
4
Aprepitant Approved, Investigational Phase 4 170729-80-3 6918365 151165
5
Ondansetron Approved Phase 4,Not Applicable 99614-02-5 4595
6
Fosaprepitant Approved Phase 4 172673-20-0 219090
7
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
8
Atropine Approved, Vet_approved Phase 4 51-55-8, 5908-99-6 174174
9
Meclizine Approved Phase 4,Phase 2,Phase 1 569-65-3 4034
10
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
11
Racepinephrine Approved Phase 4 329-65-7 838
12
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
13
Substance P Investigational Phase 4 33507-63-0 44359816
14 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
15 Histamine H1 Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
16 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
17 Histamine Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
18
Histamine Phosphate Phase 4,Phase 2,Phase 1,Not Applicable 51-74-1 65513
19 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
20 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
21 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
22 Muscarinic Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
23 Scopolamine hydrobromide Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 114-49-8
24 Mydriatics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
25 Bromides Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
26 Cholinergic Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
27 Adjuvants, Anesthesia Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
28 Butylscopolammonium Bromide Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
29 Parasympatholytics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
30 Central Nervous System Depressants Phase 4,Not Applicable
31 Dermatologic Agents Phase 4,Not Applicable
32 Anti-Allergic Agents Phase 4,Phase 2,Phase 1,Not Applicable
33 Anesthetics, Local Phase 4,Not Applicable
34 Antiemetics Phase 4,Phase 2,Phase 1,Not Applicable
35 Gastrointestinal Agents Phase 4,Phase 2,Phase 1,Not Applicable
36 Antipruritics Phase 4,Not Applicable
37 Hypnotics and Sedatives Phase 4,Not Applicable
38 Psychotropic Drugs Phase 4,Not Applicable
39 Anti-Anxiety Agents Phase 4,Not Applicable
40 Neurokinin-1 Receptor Antagonists Phase 4
41 Serotonin Antagonists Phase 4,Not Applicable
42 Tranquilizing Agents Phase 4,Not Applicable
43 Antipsychotic Agents Phase 4,Not Applicable
44 neurokinin A Phase 4
45 Serotonin Agents Phase 4,Not Applicable
46 Cholinesterase Inhibitors Phase 4,Not Applicable
47 rGLP-1 protein Phase 4
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
49
s 1 (combination) Phase 4
50 Epinephryl borate Phase 4

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 Countermeasures to Reduce Sensorimotor Impairment and Space Motion Sickness Resulting From Altered Gravity Levels Completed NCT02136420 Phase 4 Promethazine;Placebo
2 The Effect of Combining Aprepitant With Ondansetron in High-risk Patients for Postoperative Nausea and Vomiting Completed NCT01897337 Phase 4 Aprepitant;placebo
3 Comparison of the Effects of Neostigmine With Sugammadex on Postoperative Nausea and Vomiting. Completed NCT02286752 Phase 4 Neostigmine;sugammadex
4 Motion Sickness Medications and Vestibular Time Constant Recruiting NCT03270839 Phase 4 Bonine 25Mg Chewable Tablet;Kwells;Placebo Oral Tablet
5 Clinical Evaluation of the Use of Ginger Extract in the Management of Motion Sickness Not yet recruiting NCT03755596 Phase 4 Z. officinale extract
6 A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects Terminated NCT02802514 Phase 4 Albiglutide 50mg;Albiglutide matching placebo;Exenatide 10microgram;Exenatide placebo (saline)
7 Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria Completed NCT00785135 Phase 3
8 Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray Terminated NCT02155309 Phase 2, Phase 3 Scopolamine;Placebo
9 Levo Phencynonate Hydrochloride for the Prevention of Seasickness Completed NCT02241629 Phase 2 placebo;levo phencynonate hydrochloride
10 Effects of Transdermal Scopolamine on Occupational Performance Completed NCT00374478 Phase 2 Scopolamine
11 Meclizine as a Potential Smoking Cessation Treatment Completed NCT01443858 Phase 2 Meclizine;Nicotine Patch;Placebo
12 Phase II Dose-ranging Study of APD421 in PONV Completed NCT01510704 Phase 2 APD421;Placebo
13 Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV) Completed NCT00895830 Phase 2 APD405;Placebo
14 Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness Recruiting NCT03772340 Phase 2 Tradipitant;Placebo
15 Efficacy of Ginger Extract (Compare Between the Ginger Preparation of Ancient Concept of Thai Traditional Practitioner, Standard Drug and Placebo) by Using Pain Score to Evaluate After Pain of Three Groups of First Normal Postpartum Women. Enrolling by invitation NCT03617900 Phase 1, Phase 2 Ginger;Placebo oral capsule;Paracetamol
16 4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine Withdrawn NCT03578354 Phase 2 4-aminopyridine;Atenolol
17 A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants. Completed NCT02839135 Phase 1 Reformulated scopolamine patch;Marketed scopolamine patch
18 Meclizine for Hepatocellular Carcinoma Recruiting NCT03253289 Phase 1 Meclizine Oral Tablet
19 Research on Quantification of VR(Virtual Reality) Related Stress and Relaxation Unknown status NCT02986555 Not Applicable
20 Evaluation and Characterization of Motion Sickness on Passengers Sailing on the Astrolabe Unknown status NCT02911402
21 A Double-blind Comparison of Scopolamine With Cinnarizin for Prevention of Simulator Sickness Unknown status NCT01198106 Not Applicable scopolamine;cinnarizine
22 Parabolic Flight Induced Neuroplasticity Studied With Advanced Magnetic Resonance Imaging Methods Unknown status NCT02517216 Not Applicable
23 Influence of Gravity on the Perception of Egocentric Distance (Blindpulling) Unknown status NCT02508545 Not Applicable
24 Effects of Inverted Vision on Pointing and Grasping in Parabolic Flight Unknown status NCT02885844 Not Applicable
25 Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines? Completed NCT00360282 Not Applicable Rizatriptan
26 Effect of Transcutaneous Vagal Nerve Stimulation on Reducing Visually Induced Motion Sickness in Healthy Volunteers Completed NCT02177890 Not Applicable
27 Study of Hierarchy of Afferents in Postural Control of Children With Dyslexia Completed NCT02879786 Not Applicable
28 Risk Factors for Post Operative Nausea and Vomiting(PONV) in Patients Underwent Gynecological Operation Under General Anesthesia Completed NCT01020201
29 Assessment of Cholinergic and Cognitive Function Using Pharmacologic ASL-Perfusion MRI Completed NCT01379001 Not Applicable Scopolamine;Placebo;Donepezil
30 Anti Emetic Efficacy of Combination of Ramosetron and Premixture of Naloxone With Patient-controlled Analgesia Completed NCT02416115 Not Applicable Ramosetron;Naloxone;saline;Morphine
31 Virtual Reality Distraction for Procedural Pain Management and Anxiety in Children With Burn Injuries : A Pilot Study Completed NCT02794103 Not Applicable
32 Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin Completed NCT00729677
33 Influence of Couch Tracking Motion Completed NCT02820532 Not Applicable
34 Training Using Immersive Virtual Reality Completed NCT03721094 Not Applicable
35 The Jintronix Interactive System for Upper Extremity Rehabilitation Training Post Stroke Completed NCT03759145 Not Applicable
36 Evaluation of Pain and Postoperative Nausea Vomiting Incidence in Outpatient Surgery at IUCT-Oncopole Hospital Completed NCT03669328
37 Risk Factors for Postoperative Nausea, Vomiting and Pruritus Recruiting NCT03178058
38 3-dimensional Versus 2-dimensional Laparoscopy of Ovarian Cyst Recruiting NCT03453333 Not Applicable
39 Virtual Reality in Labor and Delivery for Reduction in Pain Recruiting NCT03437031 Not Applicable
40 Transcranial Electrical Stimulation for Mal de Debarquement Syndrome Recruiting NCT02540616 Not Applicable
41 Transcranial Magnetic Stimulation for Mal de Debarquement Syndrome Recruiting NCT02470377 Not Applicable
42 The INCREASE Study - Delaying the Onset of Alzheimer's Symptomatic Expression Recruiting NCT02849639 Early Phase 1 Scopolamine patch
43 Predictive Progressive Factors of Adolescent Idiopathic Scoliosis Recruiting NCT02862392
44 Optimizing a Home-based Virtual Reality Exercise Program for Chronic Stroke Patients: A Telerehabilitation Approach Recruiting NCT03759106 Not Applicable
45 Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients Not yet recruiting NCT03560583 Not Applicable Metoclopramide;Placebo Oral Tablet
46 Assessment of Visual Function With a Portable Brain-computer Interface Not yet recruiting NCT03760055
47 Virtual Reality and tACS for Performance Enhancement Not yet recruiting NCT03636126 Not Applicable
48 The Effect of Gum Chewing on Postoperative Ileus Withdrawn NCT00879294 Not Applicable
49 Intraoperative Electronic Reminder Module to Enhance Postoperative Nausea and Vomiting Prophylaxis Withdrawn NCT02830412 Not Applicable
50 Rescue Emetic Therapy for Children Having Elective Surgery Withdrawn NCT01067677 Not Applicable Metaclopramide;Ondansetron;diphenhydramine;Saline

Search NIH Clinical Center for Motion Sickness

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: motion sickness

Genetic Tests for Motion Sickness

Anatomical Context for Motion Sickness

MalaCards organs/tissues related to Motion Sickness:

41
Brain, Eye, Skin, Testes, Heart, Breast, Liver

Publications for Motion Sickness

Articles related to Motion Sickness:

(show top 50) (show all 1050)
# Title Authors Year
1
An evaluation for VR glasses system user experience: The influence factors of interactive operation and motion sickness. ( 30487101 )
2019
2
Motion sickness as metaphor: engaging with diversity in STEM. ( 30540205 )
2019
3
Effects of unexpected visual motion on postural sway and motion sickness. ( 29764619 )
2018
4
Predicting vection and visually induced motion sickness based on spontaneous postural activity. ( 29181555 )
2018
5
Assessment of Olfactory Perception in Individuals with Motion Sickness. ( 29673427 )
2018
6
Postural time-to-contact as a precursor of visually induced motion sickness. ( 29589080 )
2018
7
Effect of Prophylactic Medication on Associated Dizziness and Motion Sickness in Migraine. ( 29227453 )
2018
8
Visual Occlusion Decreases Motion Sickness in a Flight Simulator. ( 29490570 )
2018
9
Acupuncture relieves motion sickness via the IRI^-ERK1/2-dependent insulin receptor signalling pathway. ( 29436382 )
2018
10
Reduction of Motion Sickness Through Targeting Histamine<i>N</i>-Methyltransferase in the Dorsal Vagal Complex of the Brain. ( 29298819 )
2018
11
Virtual reality sickness questionnaire (VRSQ): Motion sickness measurement index in a virtual reality environment. ( 29477332 )
2018
12
The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance &amp;amp; cognitive function. ( 29522648 )
2018
13
Allocating less attention to central vision during vection is correlated with less motion sickness. ( 29325490 )
2018
14
Intravestibular Balance and Motion Sickness. ( 29463358 )
2018
15
Relationship between motion sickness susceptibility and vestibulo-ocular reflex gain and phase. ( 29689763 )
2018
16
Higher Asymmetry Ratio and Refixation Saccades in Individuals with Motion Sickness. ( 29401064 )
2018
17
Prevalence of motion sickness in various vestibular disorders: a study on 749 patients. ( 29982849 )
2018
18
Targeting TRPV1 to relieve motion sickness symptoms in mice by electroacupuncture and gene deletion. ( 29985388 )
2018
19
A Case Study of Severe Space Motion Sickness. ( 30020061 )
2018
20
More vection means more velocity storage activity: a factor in visually induced motion sickness? ( 30120498 )
2018
21
An Active Suspension System for Mitigating Motion Sickness and Enabling Reading in a Car. ( 30126515 )
2018
22
A comparative study of cybersickness during exposure to virtual reality and "classic" motion sickness: are they different? ( 30284516 )
2018
23
Responding to Other People's Posture: Visually Induced Motion Sickness From Naturally Generated Optic Flow. ( 30349501 )
2018
24
The Neurophysiology and Treatment of Motion Sickness. ( 30406755 )
2018
25
No Gain No Pain: Relations Between Vestibulo-Ocular Reflexes and Motion Sickness in Mice. ( 30483206 )
2018
26
Anti-cholinergics mecamylamine and scopolamine alleviate motion sickness-induced gastrointestinal symptoms through both peripheral and central actions. ( 30543811 )
2018
27
Passive restraint reduces visually induced motion sickness in older adults. ( 28150962 )
2017
28
Electroacupuncture Could Reduce Motion Sickness Susceptibility in Healthy Male Adults: A Double-Blinded Study. ( 29279732 )
2017
29
Orientation Preferences and Motion Sickness Induced in a Virtual Reality Environment. ( 28923138 )
2017
30
Determinants of Motion Sickness in Tilting Trains: Coriolis/Cross-Coupling Stimuli and Tilt Delay. ( 28555125 )
2017
31
The efficacy of airflow and seat vibration on reducing visually induced motion sickness. ( 28634889 )
2017
32
Motion sickness increases functional connectivity between visual motion and nausea-associated brain regions. ( 28245927 )
2017
33
Effects of Physical Driving Experience on Body Movement and Motion Sickness During Virtual Driving. ( 29046173 )
2017
34
Effects of decades of physical driving on body movement and motion sickness during virtual driving. ( 29121059 )
2017
35
Sex and Age Differences in Motion Sickness in Rats: The Correlation with Blood Hormone Responses and Neuronal Activation in the Vestibular and Autonomic Nuclei. ( 28261089 )
2017
36
A Historical View of Motion Sickness-A Plague at Sea and on Land, Also with Military Impact. ( 28421029 )
2017
37
Brain Activation by H1 Antihistamines Challenges Conventional View of Their Mechanism of Action in Motion Sickness: A Behavioral, c-Fos and Physiological Study in Suncus murinus (House Musk Shrew). ( 28659825 )
2017
38
Low level of swiprosin-1/EFhd2 in vestibular nuclei of spontaneously hypersensitive motion sickness mice. ( 28128226 )
2017
39
Correlations between individual susceptibility to visually induced motion sickness and decaying time constant of after-nystagmus. ( 28502398 )
2017
40
Prevalence, Predictors, and Prevention of Motion Sickness in Zero-G Parabolic Flights. ( 28061915 )
2017
41
Effect of exposure to short-wavelength light on susceptibility to motion sickness. ( 28538515 )
2017
42
History of High Motion Sickness Susceptibility Predicts Vestibular Dysfunction Following Sport/Recreation-Related Concussion. ( 29189336 )
2017
43
Vection is the main contributor to motion sickness induced by visual yaw rotation: Implications for conflict and eye movement theories. ( 28380077 )
2017
44
Cross-coupling vestibular stimulation: motion sickness and the vestibulo-sympathetic reflex. ( 28455665 )
2017
45
Storage of passive motion pattern in hippocampal CA1 region depends on CaMKII/CREB signaling pathway in a motion sickness rodent model. ( 28230177 )
2017
46
Evaluation of Motion Sickness Induced by 3D Video Clips. ( 26832611 )
2016
47
Contribution of intra-vestibular sensory conflict to motion sickness and dizziness in migraine disorders. ( 27385797 )
2016
48
Motion sickness and sopite syndrome associated with parabolic flights: a case report. ( 26624575 )
2016
49
Psychometric Properties of the Greek Version of the Gianaros Motion Sickness Assessment Questionnaire. ( 27779955 )
2016
50
Motion sickness in ancient China: Seasickness and cart-sickness. ( 27432177 )
2016

Variations for Motion Sickness

Expression for Motion Sickness

Search GEO for disease gene expression data for Motion Sickness.

Pathways for Motion Sickness

GO Terms for Motion Sickness

Cellular components related to Motion Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.02 ADRA2A AQP1 HTR1A HTR3A HTR7

Biological processes related to Motion Sickness according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.88 ADRA2A AVP EXT2 HTR1A HTR3A HTR7
2 G protein-coupled receptor signaling pathway GO:0007186 9.83 ADRA2A AVP HTR1A HTR7 TAC1
3 cellular response to hormone stimulus GO:0032870 9.49 ADRA2A FOS
4 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.48 HTR1A HTR7
5 renal water homeostasis GO:0003091 9.46 AQP1 AVP
6 chemical synaptic transmission GO:0007268 9.46 HTR1A HTR3A HTR7 TAC1
7 water transport GO:0006833 9.37 AQP1 AVP
8 multicellular organismal water homeostasis GO:0050891 9.32 AQP1 AVP
9 serotonin receptor signaling pathway GO:0007210 9.26 HTR1A HTR3A
10 positive regulation of saliva secretion GO:0046878 8.96 AQP1 TAC1
11 vasoconstriction GO:0042310 8.8 AVP HTR1A HTR7

Molecular functions related to Motion Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neurotransmitter receptor activity GO:0030594 9.16 HTR1A HTR7
2 G protein-coupled serotonin receptor activity GO:0004993 8.96 HTR1A HTR7
3 serotonin binding GO:0051378 8.62 HTR1A HTR3A

Sources for Motion Sickness

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....